According to the Measures of Beijing Municipality for Science and Technology Awards, through the review by the Municipal Science and Technology Awards Review Committee and the approval by the municipal government, ACCB’s project “development and application of gene companion diagnostic technology products for lung cancer and colorectal cancer” was awarded the third prize of 2018 “Beijing Science and Technology Awards”.

“Beijing Science and Technology Awards” appraisal is conducted once a year. The project submitted by ACCB competed with the projects submitted by famous universities, research institutes, medical institutions and various enterprises and institutions in Beijing and finally won this prize, which is not only a recognition of ACCB’s independent innovation level and practical application achievements in the gene companion diagnostic field over the years, but also a manifestation of ACCB’s confidence to continuously implement its vision of serving the development of Healthy China Initiative with precision medicine innovation in the future.

On March 1, 2019, “Beijing Science and Technology Awards Conference & 2019 National Science and Technology Innovation Center Construction Work Conference” was held at the Beijing Convention Center. The conference commended the technological achievements that won the 2018 Beijing Science and Technology Awards. CAI Qi, Member of the Political Bureau of the CPC Central Committee and Secretary of the CPC Beijing Municipal Committee, CHEN Jining, Deputy Secretary of the CPC Beijing Municipal Committee and Mayor of Beijing, and other leaders presented awards to science and technology workers and expressed their high respect and warm congratulations on their contribution to the construction of the national science and technology innovation center.

▲ The picture shows the conference site

China has a large number of patients with cancer. For a long time, the incidence and mortality of patients with cancer have remained high, posing a serious threat to the lives and health of our people. The trend of lung cancer and colorectal cancer is dire. According to the latest national cancer statistics released by the National  Cancer Center in January 2019, the mortality rate of patients with lung cancer ranks first among the patients with cancers, and colorectal cancer also ranks in front.

According to various diagnostic and treatment standards for lung cancer and colorectal cancer, and considering the detection of the corresponding companion diagnostic gene with specific drugs, accurate and efficient detection means are provided for clinicians to implement personalized treatment, and this is an important means for cancer treatment. In recent years, ACCB has independently developed EGFR, KRAS, BRAF, PIK3CA, NRAS, ALK and other gene mutation detection kits for the companion diagnosis of lung cancer and colorectal cancer, invented the gene mutation quantitative detection technology and kits, and successively obtained 7 medical device registration certificates (Class III), and its 6 products have won Beijing New Technology and New Product Certificate. At the same time, in the field of gene detection kits, it has successively developed nucleic acid extraction automation instruments and kits and gene detection data analysis softwares for rapid and accurate acquisition of gene diction results, thus achieving the goal of “precise treatment” and satisfying clinical diagnosis and treatment needs.

The gene detection kit products developed by ACCB and the gene detection services of ACCB Medical Test Institute have been extended to more than 200 units in more than 20 provinces and municipalities acrossChina. The kits are at the leading level in terms of technical indicators inChinaand can completely replace similar imported products. They have achieved good social and economic benefits in the field of gene companion diagnosis for lung cancer and colorectal cancer in Beijing and other provinces and cities, and significantly promoted the development of gene companion diagnosis and precision medicine industry.

Innovation is the first driving force to lead a country’s development, and is also the core kinetic energy to promote high-quality growth of enterprises. In the field of tumor diagnosis and treatment, the most direct quantitative presentation of technological innovation is “precision”. Since its inception, ACCB has not only increased the core technology research and development efforts to improve the “precision” of tumor diagnosis, but also continuously expanded the “broadness” of the transformation of technological achievements in precision medicine through the establishment of a platform for the transformation of precision medicine achievements. A group of enterprises with original innovation advantages stand out through incubation.

By staying true to our mission, we march forward through innovation. In the future, ACCB will continue to release the innovation potential through technological innovation and acceleration of transformation of high-quality technological achievements, stride across the technology gaps through innovation driving, strive to achieve precise medicine products and services with a lower cost and greater accessibility to benefit the public, contribute to the development of precision medicine and companion diagnostic industry, and infuse vitality into Healthy China Initiative.